10.1021/acsmedchemlett.9b00569.s001
Azzurra Stefanucci
Azzurra
Stefanucci
Marilisa Pia Dimmito
Marilisa Pia
Dimmito
Gabriela Molnar
Gabriela
Molnar
John M. Streicher
John M.
Streicher
Ettore Novellino
Ettore
Novellino
Gokhan Zengin
Gokhan
Zengin
Adriano Mollica
Adriano
Mollica
Developing Cyclic Opioid Analogues: Fluorescently
Labeled Bioconjugates of Biphalin
American Chemical Society
2020
bioconjugate
characterization
δ- opioid receptor
probe
binding
agent
vivo
DOR
motif
analogue
nm
novel opioid peptides fluorescently
dansyl-maleimide
application
affinity
compound 1 D
fluorescence emission spectrum
synthesis
Cyclic Opioid Analogues
Biphalin
importance
control drug release
potency
imaging
1 D
cyclic biphalin derivatives
Fluorescently Labeled Bioconjugates
toxicity
2020-01-10 14:43:02
Journal contribution
https://acs.figshare.com/articles/journal_contribution/Developing_Cyclic_Opioid_Analogues_Fluorescently_Labeled_Bioconjugates_of_Biphalin/11568738
The development of
bioconjugates is of pivotal importance in medicinal
chemistry due to their potential applications as therapeutic agents
to improve the targeting of specific diseases, decrease toxicity,
or control drug release. In this work we achieved the synthesis and
characterization of three novel opioid peptides fluorescently labeled,
analogues of cyclic biphalin derivatives, namely <b>1D</b>, <b>1C</b>, and <b>2C</b>. Among them, compound <b>1D</b>, containing a dansyl-maleimide motif, exhibited an excellent binding
affinity and functional potency for the δ-opioid receptor (DOR). <b>1D</b> also demonstrated a strong fluorescence emission spectrum
ranging from 300 to 700 nm. These features could be highly desirable
for medical and biological applications needed for targeting the DOR,
including <i>in vivo</i> imaging, and as a lead for the
design of fluorescent probes.